At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels
This partnership has led to a 10% boost in delivery speed
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Subscribe To Our Newsletter & Stay Updated
